Predix Pharmaceuticals prepares for public offering

Predix Pharmaceuticals, which has facilities in Lexington, Massachusetts, and Israel, has filed to go public. The company raised $43 million in its third round of venture capital last January. Researchers at Predix are investigating compounds for general anxiety disorder, hypertension and Alzheimer's.

- read this report from Globes for more

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.